CompletedNot Applicable

Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS

United States7 participantsStarted 2021-09-09

Plain-language summary

This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55, who are currently taking ART and reporting less than 100% adherence. The aims of the study are to see whether the device can achieve \>95% ART adherence among all participants averaged over 90 days and to perform usability testing using the System Usability Scale and Net Promoter scores.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-65 years of age * Prescription for at least one existing ART * Has expressed difficulty with medication adherence (question screen) * Access to a personal smart phone and a Wi-Fi connection * Ability to read and write English Exclusion Criteria: * Illicit drug use within the past 6 months (excl. marijuana) * Diagnosis of dementia * Clinical study participation within the previous 3 months * Changes to ART regimen within the previous 2 months * Anticipated change to ART therapy within the study period

What they're measuring

Rate of Medication Adherence

Timeframe: 90 days

Trial details

NCT IDNCT05454514

SponsorCharles Gellman

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-05-31

Results submitted2024-10-21

View on ClinicalTrials.gov More HIV Infections trials